Innovating Works
IMI2-2017-11-01
IMI2-2017-11-01: Exploitation of IMI project results
Specific Challenge:A key challenge of any research funding scheme is to ensure that significant results, outputs and/or data generated during the lifetime of a project remain available to be further exploited for maximum beneficial impact after the project finishes. Often, important scientific results reach the public domain via publication in relevant scientific journals. However, for some important results – which may include databases, biobanks, new tools, important clinical samples, demonstration models, etc. – the route to becoming available to the wider scientific community or being exploited fully, remains a difficult path. Realising the full potential of a project’s important results within the timeframe available is not always possible and might sometimes only be achieved through the involvement of additional expertise from outside of the project.
Sólo fondo perdido 5M €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 24-10-2017.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:A key challenge of any research funding scheme is to ensure that significant results, outputs and/or data generated during the lifetime of a project remain available to be further exploited for maximum beneficial impact after the project finishes. Often, important scientific results reach the public domain via publication in relevant scientific journals. However, for some important results – which may include databases, biobanks, new tools, important clinical samples, demonstration models, etc. – the route to becoming available to the wider scientific community or being exploited fully, remains a difficult path. Realising the full potential of a project’s important results within the timeframe available is not always possible and might sometimes only be achieved through the involvement of additional expertise from outside of the project.


Scope:This call for proposals aims at providing a starting/short term support to develop enabling solutions to ensure that significant results from IMI projects become fully exploitable, available to all relevant end users, and/or fully sustainable in the long term and in their own right. This will ensure that... ver más

Specific Challenge:A key challenge of any research funding scheme is to ensure that significant results, outputs and/or data generated during the lifetime of a project remain available to be further exploited for maximum beneficial impact after the project finishes. Often, important scientific results reach the public domain via publication in relevant scientific journals. However, for some important results – which may include databases, biobanks, new tools, important clinical samples, demonstration models, etc. – the route to becoming available to the wider scientific community or being exploited fully, remains a difficult path. Realising the full potential of a project’s important results within the timeframe available is not always possible and might sometimes only be achieved through the involvement of additional expertise from outside of the project.


Scope:This call for proposals aims at providing a starting/short term support to develop enabling solutions to ensure that significant results from IMI projects become fully exploitable, available to all relevant end users, and/or fully sustainable in the long term and in their own right. This will ensure that the significant outputs, important samples and/or data that have been generated by the large public-private investments are maintained and made available for future research by the whole scientific community and that important findings are integrated in general research and medical practice in support of the objectives of IMI2. The work to be supported will consist mainly of activities and measures to make the results available to the broader scientific community and as such may include measures to enable technology transfer and the analysis of regulatory aspects, as well as the standardisation and transfer of samples, databases, tools, etc. to sustainable infrastructures. In addition, the work may also encompass further activities should novel solutions/tools/methods be required to achieve the objectives of sustaining the results and ensuring their full impact. These could include adaptation of technologies to enable wider engagement, development of novel standardisation and/or interoperability measures, further development of scientific and business solutions, etc., as appropriate.

Applicants should be aware that only the project results identified in the list of results available on the IMI2 JU website http://www.imi.europa.eu/content/imi-2-call-11 are within the scope of this Call. As such, applicants must clearly indicate through their proposals which results they are utilising.

The relevant consortia will provide the necessary access rights to any potential applicant in furtherance of the call objectives and according to applicable IMI rules


Expected Impact:

It is expected that proposals selected for award under this call will lead to a sustainable future and full exploitation for key IMI project results. It is also envisaged that sustaining these results will stimulate the development of an open innovation model in biopharmaceutical research and contribute to the achievement of IMI2 objectives.

Selected proposals should demonstrate an appreciation of the impact of exploiting the results with respect to long-term sustainability; an impact on R&D, regulatory, clinical and healthcare practice, as relevant; strengthening the competitiveness and industrial leadership and/or addressing specific societal challenges, and improving European citizens' health and wellbeing, when appropriate.


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:A key challenge of any research funding scheme is to ensure that significant results, outputs and/or data generated during the lifetime of a project remain available to be further exploited for maximum beneficial impact after the project finishes. Often, important scientific results reach the public domain via publication in relevant scientific journals. However, for some important results – which may include databases, biobanks, new tools, important clinical samples, demonstration models, etc. – the route to becoming available to the wider scientific community or being exploited fully, remains a difficult path. Realising the full potential of a project’s important results within the timeframe available is not always possible and might sometimes only be achieved through the involvement of additional expertise from outside of the project. Specific Challenge:A key challenge of any research funding scheme is to ensure that significant results, outputs and/or data generated during the lifetime of a project remain available to be further exploited for maximum beneficial impact after the project finishes. Often, important scientific results reach the public domain via publication in relevant scientific journals. However, for some important results – which may include databases, biobanks, new tools, important clinical samples, demonstration models, etc. – the route to becoming available to the wider scientific community or being exploited fully, remains a difficult path. Realising the full potential of a project’s important results within the timeframe available is not always possible and might sometimes only be achieved through the involvement of additional expertise from outside of the project.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application :
The IMI2 11th Call for proposals topic text, the Annex Table A of projects results for IMI2 Call 11 as well as the Call Conditions are available here.
1. List of countries and applicable rules for funding: described in article 10(2) of Regulation N° 1290/2013 of 11 December 2013 laying down the rules for participation and dissemination in Horizon 2020 and in article 1 of the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
2. Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
3. Evaluation
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative timetable for evaluation and grant agreement:
Information on the outcome of single-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 month from the date of informing successful applicants.
5. Provisions, proposal templates and evaluation form...
Please read carefully all provisions below before the preparation of your application :
The IMI2 11th Call for proposals topic text, the Annex Table A of projects results for IMI2 Call 11 as well as the Call Conditions are available here.
1. List of countries and applicable rules for funding: described in article 10(2) of Regulation N° 1290/2013 of 11 December 2013 laying down the rules for participation and dissemination in Horizon 2020 and in article 1 of the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
2. Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014.
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
3. Evaluation
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative timetable for evaluation and grant agreement:
Information on the outcome of single-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 month from the date of informing successful applicants.
5. Provisions, proposal templates and evaluation forms:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Proposal templates are available after entering the submission tool
Standard evaluation form 
IMI2 Model Grant Agreement 
Clinical trial template – the Clinical Trial template is compulsory at stage 2 only !
6. Additional provisions:
Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
This topic participates per default in the open access to research data pilot which aims to improve and maximise access to and re-use of research data generated by projects:
- The pilot applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available for open access and need to describe their approach in a Data Management Plan (to be provided within six months after the project start).
- Note that the evaluation phase proposals will not be evaluated more favourably because they are part of the Pilot, and will not be penalised for opting out of the Pilot.
- Projects can at any stage opt-out of the pilot.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Further information on the Open Research Data Pilot is made available in the H2020 Online Manual: http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/open-access-dissemination_en.htm 
7. Additional documents:
Summary of the most relevant provisions for participating in IMI2 actions
IMI2 Annual Work Plan 2017
IMI2 Regulators Guidance tool for researchers
IMI JU derogation to H2020 Rules for Participation
Horizon 2020 Rules for Participation
Horizon 2020 Regulation of Establishment
Horizon 2020 Specific Programme
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
El presupuesto total de la convocatoria asciende a
Presupuesto total de la convocatoria.
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-JTI-IMI2-2017-11-single-stage Exploitation of IMI project results Specific Challenge:A key challenge of any research funding scheme is to ensure that significant results, outputs and/or data generated durin...
Sin info.
IMI2-2017-12-05 European Health Data Network (EHDN)
en consorcio:
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-10 Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
en consorcio: Specific Challenge:Neurotoxicity (used in the context of this document as “any adverse effect on the central nervous system (CNS) or periphe...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-02 Genome-Environment Interactions in Inflammatory Skin Disease
en consorcio: Specific Challenge:Inflammatory skin diseases affect a significant percentage of our global population. Atopic Dermatitis (AD) affects appro...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-08 Human Tumour Microenvironment Immunoprofiling
en consorcio: Specific Challenge:To improve therapy, the understanding of the tumour microenvironment needs to evolve. Firstly, the understanding of tumou...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de
IMI2-2017-13-14 Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
en consorcio: Specific Challenge:On average it takes about 14 years for a new drug to travel from the research lab to market approval at an average cost o...
Cerrada hace 7 años | Próxima convocatoria prevista para el mes de